



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 61732

Title: Risk stratification and geographical mapping of Brazilian inflammatory bowel diseases patients during COVID-19 outbreak: Results from a nationwide survey

Reviewer's code: 05223442

Position: Editorial Board

Academic degree: FICS, MD, MSc

Professional title: Academic Fellow, Lecturer, Senior Researcher, Surgeon

Reviewer's Country/Territory: Liberia

Author's Country/Territory: Brazil

Manuscript submission date: 2020-12-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-12-22 17:32

Reviewer performed review: 2020-12-30 14:09

Review time: 7 Days and 20 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The IBD societies and experts have strongly recommended that patients should not discontinue their IBD medications. 1. Did patients with IBD infected COVID-19 continued their IBD medications? 2. Is there any known difference between CD and UC in terms of COVID-19 infection risk and outcome? 3. What were the common manifestation of COVID-19 in patients with IBD?